Logo image of NURS.CA

HYDREIGHT TECHNOLOGIES INC (NURS.CA) Stock Fundamental Analysis

TSX-V:NURS - CA44877L1013 - Common Stock

3.78 CAD
-0.22 (-5.5%)
Last: 9/5/2025, 7:00:00 PM
Fundamental Rating

5

Taking everything into account, NURS scores 5 out of 10 in our fundamental rating. NURS was compared to 9 industry peers in the Health Care Technology industry. NURS has a great financial health rating, but its profitability evaluates not so good. NURS is not priced too expensively while it is growing strongly. Keep and eye on this one!


Dividend Valuation Growth Profitability Health

Quickly go to:

2

1. Profitability

1.1 Basic Checks

NURS had negative earnings in the past year.
NURS had a positive operating cash flow in the past year.
NURS.CA Yearly Net Income VS EBIT VS OCF VS FCFNURS.CA Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2021 2022 2023 2024 0 -2M -4M

1.2 Ratios

Looking at the Return On Assets, with a value of -0.91%, NURS is in the better half of the industry, outperforming 77.78% of the companies in the same industry.
Looking at the Return On Equity, with a value of -2.40%, NURS is in the better half of the industry, outperforming 77.78% of the companies in the same industry.
Industry RankSector Rank
ROA -0.91%
ROE -2.4%
ROIC N/A
ROA(3y)-98.35%
ROA(5y)N/A
ROE(3y)N/A
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
NURS.CA Yearly ROA, ROE, ROICNURS.CA Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2021 2022 2023 2024 0 500 1K 1.5K

1.3 Margins

NURS's Gross Margin of 34.69% is in line compared to the rest of the industry. NURS outperforms 55.56% of its industry peers.
NURS's Gross Margin has declined in the last couple of years.
The Profit Margin and Operating Margin are not available for NURS so they could not be analyzed.
Industry RankSector Rank
OM N/A
PM (TTM) N/A
GM 34.69%
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y-12.69%
GM growth 5YN/A
NURS.CA Yearly Profit, Operating, Gross MarginsNURS.CA Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2021 2022 2023 2024 0 50 -50 -100

More info and screens

7

2. Health

2.1 Basic Checks

NURS does not have a ROIC to compare to the WACC, probably because it is not profitable.
The number of shares outstanding for NURS has been increased compared to 1 year ago.
There is no outstanding debt for NURS. This means it has a Debt/Equity and Debt/FCF ratio of 0 and it is amongst the best of the sector and industry.
NURS.CA Yearly Shares OutstandingNURS.CA Yearly Shares OutstandingYearly Shares Outstanding 2021 2022 2023 2024 10M 20M 30M 40M
NURS.CA Yearly Total Debt VS Total AssetsNURS.CA Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2021 2022 2023 2024 1M 2M 3M

2.2 Solvency

An Altman-Z score of 21.43 indicates that NURS is not in any danger for bankruptcy at the moment.
NURS has a better Altman-Z score (21.43) than 88.89% of its industry peers.
There is no outstanding debt for NURS. This means it has a Debt/Equity and Debt/FCF ratio of 0 and it is amongst the best of the sector and industry.
Industry RankSector Rank
Debt/Equity 0
Debt/FCF 0
Altman-Z 21.43
ROIC/WACCN/A
WACC9.2%
NURS.CA Yearly LT Debt VS Equity VS FCFNURS.CA Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2021 2022 2023 2024 -500K -1M -1.5M

2.3 Liquidity

NURS has a Current Ratio of 1.50. This is a normal value and indicates that NURS is financially healthy and should not expect problems in meeting its short term obligations.
Looking at the Current ratio, with a value of 1.50, NURS is in the better half of the industry, outperforming 66.67% of the companies in the same industry.
NURS has a Quick Ratio of 1.50. This is a normal value and indicates that NURS is financially healthy and should not expect problems in meeting its short term obligations.
With a decent Quick ratio value of 1.50, NURS is doing good in the industry, outperforming 66.67% of the companies in the same industry.
Industry RankSector Rank
Current Ratio 1.5
Quick Ratio 1.5
NURS.CA Yearly Current Assets VS Current LiabilitesNURS.CA Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2021 2022 2023 2024 1M 2M 3M 4M

More info and screens

8

3. Growth

3.1 Past

The Earnings Per Share has grown by an impressive 96.24% over the past year.
Looking at the last year, NURS shows a very strong growth in Revenue. The Revenue has grown by 37.23%.
Measured over the past years, NURS shows a very strong growth in Revenue. The Revenue has been growing by 137.35% on average per year.
EPS 1Y (TTM)96.24%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%106.17%
Revenue 1Y (TTM)37.23%
Revenue growth 3Y137.35%
Revenue growth 5YN/A
Sales Q2Q%34.42%

3.2 Future

Based on estimates for the next years, NURS will show a very strong growth in Earnings Per Share. The EPS will grow by 285.65% on average per year.
NURS is expected to show a strong growth in Revenue. In the coming years, the Revenue will grow by 130.33% yearly.
EPS Next Y876.92%
EPS Next 2Y466.62%
EPS Next 3Y285.65%
EPS Next 5YN/A
Revenue Next Year263.78%
Revenue Next 2Y188.72%
Revenue Next 3Y130.33%
Revenue Next 5YN/A

3.3 Evolution

The Revenue growth rate is stable: in the next years the growth will be about the same than in the last years.
NURS.CA Yearly Revenue VS EstimatesNURS.CA Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2021 2022 2023 2024 2025 2026 2027 50M 100M 150M
NURS.CA Yearly EPS VS EstimatesNURS.CA Yearly EPS VS EstimatesYearly EPS VS Estimates 2025 2026 2027 0.1 0.2 0.3 0.4 0.5

More info and screens

5

4. Valuation

4.1 Price/Earnings Ratio

With a Price/Forward Earnings ratio of 12.07, NURS is valued correctly.
Based on the Price/Forward Earnings ratio, NURS is valued cheaper than 100.00% of the companies in the same industry.
Compared to an average S&P500 Price/Forward Earnings ratio of 22.69, NURS is valued a bit cheaper.
Industry RankSector Rank
PE N/A
Fwd PE 12.07
NURS.CA Price Earnings VS Forward Price EarningsNURS.CA Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 0 0 0 0 0

4.2 Price Multiples

Based on the Price/Free Cash Flow ratio, NURS is valued a bit cheaper than 77.78% of the companies in the same industry.
Industry RankSector Rank
P/FCF 4706.81
EV/EBITDA N/A
NURS.CA Per share dataNURS.CA EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0.1 0.2 0.3

4.3 Compensation for Growth

The low PEG Ratio(NY), which compensates the Price/Earnings for growth, indicates a rather cheap valuation of the company.
NURS's earnings are expected to grow with 285.65% in the coming years. This may justify a more expensive valuation.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y466.62%
EPS Next 3Y285.65%

More info and screens

0

5. Dividend

5.1 Amount

NURS does not give a dividend.
Industry RankSector Rank
Dividend Yield N/A

More info and screens

HYDREIGHT TECHNOLOGIES INC

TSX-V:NURS (9/5/2025, 7:00:00 PM)

3.78

-0.22 (-5.5%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupHealth Care Equipment & Services
GICS IndustryHealth Care Technology
Earnings (Last)08-25 2025-08-25/amc
Earnings (Next)11-24 2025-11-24
Inst Owners0.29%
Inst Owner ChangeN/A
Ins Owners2.44%
Ins Owner ChangeN/A
Market Cap176.03M
Analysts80
Price Target8.67 (129.37%)
Short Float %N/A
Short RatioN/A
Dividend
Industry RankSector Rank
Dividend Yield N/A
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)N/A
Avg EPS beat(2)N/A
Min EPS beat(2)N/A
Max EPS beat(2)N/A
EPS beat(4)N/A
Avg EPS beat(4)N/A
Min EPS beat(4)N/A
Max EPS beat(4)N/A
EPS beat(8)N/A
Avg EPS beat(8)N/A
EPS beat(12)N/A
Avg EPS beat(12)N/A
EPS beat(16)N/A
Avg EPS beat(16)N/A
Revenue beat(2)N/A
Avg Revenue beat(2)N/A
Min Revenue beat(2)N/A
Max Revenue beat(2)N/A
Revenue beat(4)N/A
Avg Revenue beat(4)N/A
Min Revenue beat(4)N/A
Max Revenue beat(4)N/A
Revenue beat(8)N/A
Avg Revenue beat(8)N/A
Revenue beat(12)N/A
Avg Revenue beat(12)N/A
Revenue beat(16)N/A
Avg Revenue beat(16)N/A
PT rev (1m)N/A
PT rev (3m)N/A
EPS NQ rev (1m)N/A
EPS NQ rev (3m)N/A
EPS NY rev (1m)N/A
EPS NY rev (3m)N/A
Revenue NQ rev (1m)N/A
Revenue NQ rev (3m)N/A
Revenue NY rev (1m)N/A
Revenue NY rev (3m)N/A
Valuation
Industry RankSector Rank
PE N/A
Fwd PE 12.07
P/S 10.23
P/FCF 4706.81
P/OCF 128.29
P/B 55.9
P/tB 130.66
EV/EBITDA N/A
EPS(TTM)0
EYN/A
EPS(NY)0.31
Fwd EY8.28%
FCF(TTM)0
FCFY0.02%
OCF(TTM)0.03
OCFY0.78%
SpS0.37
BVpS0.07
TBVpS0.03
PEG (NY)N/A
PEG (5Y)N/A
Profitability
Industry RankSector Rank
ROA -0.91%
ROE -2.4%
ROCE N/A
ROIC N/A
ROICexc N/A
ROICexgc N/A
OM N/A
PM (TTM) N/A
GM 34.69%
FCFM 0.22%
ROA(3y)-98.35%
ROA(5y)N/A
ROE(3y)N/A
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexcg growth 3YN/A
ROICexcg growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y-12.69%
GM growth 5YN/A
F-Score5
Asset Turnover2.07
Health
Industry RankSector Rank
Debt/Equity 0
Debt/FCF 0
Debt/EBITDA N/A
Cap/Depr 706.24%
Cap/Sales 7.76%
Interest Coverage N/A
Cash Conversion N/A
Profit Quality N/A
Current Ratio 1.5
Quick Ratio 1.5
Altman-Z 21.43
F-Score5
WACC9.2%
ROIC/WACCN/A
Cap/Depr(3y)341%
Cap/Depr(5y)N/A
Cap/Sales(3y)3.62%
Cap/Sales(5y)N/A
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)96.24%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%106.17%
EPS Next Y876.92%
EPS Next 2Y466.62%
EPS Next 3Y285.65%
EPS Next 5YN/A
Revenue 1Y (TTM)37.23%
Revenue growth 3Y137.35%
Revenue growth 5YN/A
Sales Q2Q%34.42%
Revenue Next Year263.78%
Revenue Next 2Y188.72%
Revenue Next 3Y130.33%
Revenue Next 5YN/A
EBIT growth 1Y91%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next Year1187.26%
EBIT Next 3Y343.1%
EBIT Next 5YN/A
FCF growth 1Y106.8%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y324.95%
OCF growth 3YN/A
OCF growth 5YN/A